Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

US cautions its citizens to threats of attacks in India
Apprehending Mumbai-type terrorist attack in various parts of India, the US today alerted its citizens to be cautious during their visit to that country and asked them to defer their travel to Andhra Pradesh as violence continues over issue of separate Telangana state.

Rupee gains 15 paise at 46.09/$ in early trade
The rupee today appreciated by 15 paise to 46.09 a dollar in early trade on sustained capital inflows into stock markets.

News of the day

Speed up 3G
Business Standard / New Delhi October 27, 2009, 0:46 IST
Business Ideas

Orchid gets ANDA's final nod from USFDA for Zaleplon Capsules

Pharma firm Orchid Chemicals & Pharmaceuticals today said it has received the final Abbreviated New Drug Application (ANDA) approval for its Zaleplon capsules from the US Food and Drug Administration, in a filing to the Bombay Stock Exchange(BSE). - Suven in talks with global drug makers for licensing deal: CEO - Wockhardt divests animal health division - Orchid Pharma settles patent row, stock up 4% - Orchid Pharma settles patent row with Schering-Plough - Ranbaxy, Aurobindo get USFDA nod for migraine drug - Ranbaxy gets GMP approval from Japan The capsules are in strengths of 5 mg and 10 mg and are used in treating insomnia, the filing added. With this approval, the total ANDA approval count of Orchid has gone up to 37 while the total ANDA filings stand at 58, it added. Earlier, on September 16, the pharma firm had received the US drug regulator"s nod for its Piperacillin and Tazobactam injection used to treat infections caused by certain bacteria and accordingly had been granted 180-days generic drug exclusivity.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009